Safety concerns lead to a split FDA panel vote on Sanofi/Lexicon diabetes drug
The first potential pill for patients with the less common type 1 diabetes, who produce no insulin, was the subject of an atypical hung jury …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
